skip to content


Hardman Research report on Abzena

13 December 2016 09:20

Hardman Research has issued a report on Abzena.

It says: "Specialist manufacturing opening new doors: Abzena is an integrated group offering a broad range of services and technologies to improve the chances of discovering and developing effective biopharmaceutical drugs. With strong footprints in both the US and UK, the company provides a fee-for-service offering with the aim of embedding its technology - 'Abzena Inside' - into commercial products, on which it will derive a long-term royalty stream.

"Abzena's integrated services can now be used from the early stages of drug discovery right through to manufacturing for Phase II clinical trials, making the company an attractive development partner."

The full report is available at:

At 9:20am: (LON:ABZA) Abzena Plc share price was 0p at 34p

Story provided by

Related Company: ABZA

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?


Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.